✦ LIBER ✦

Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study

✍ Scribed by Sabine Skodda; Andrea Flasskamp; Uwe Schlegel

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 122 KB
Volume: 26
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.23382

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progression of dysprosody in Parkinson's

Progression of dysprosody in Parkinson's disease over time—A longitudinal study

✍ Sabine Skodda; Heiko Rinsche; Uwe Schlegel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Abstract Parkinsonian speech or hypokinetic dysarthria results from a multidimensional impairment of phonation, articulation, and prosody. Although the dysprosody in Parkinson's disease (PD) is well described (alterations in speech rate and pause time, speech intensity and pitch variation), litt

UPDRS activity of daily living score as

UPDRS activity of daily living score as a marker of Parkinson's disease progression

✍ Madaline B. Harrison; Scott A. Wylie; Robert C. Frysinger; James T. Patrie; Dian 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We ex

Substantia nigra hyperechogenicity as a

Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease

✍ Katherine J. Schweitzer; Rüdiger Hilker; Uwe Walter; Lothar Burghaus; Daniela Be 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract Increased echogenic size (hyperechogenicity) of the substantia nigra (SN) is a characteristic transcranial sonography finding in patients with Parkinson's disease (PD). The SN echogenic size does not change in the course of the disease. In order to see whether this stable ultrasound mar

Rate of clinical progression in Parkinso

Rate of clinical progression in Parkinson's disease. A prospective study

✍ Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate

Progression of dopaminergic degeneration

Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study

✍ Walter Pirker; Schiva Djamshidian; Susanne Asenbaum; Willibald Gerschlager; Gott 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

## Abstract Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [^123^I]β‐CIT as a label of dopamine

A longitudinal study of neuropsychologic

A longitudinal study of neuropsychological change in individuals with Parkinson's disease

✍ Tamiko Azuma; Robyn F. Cruz; Kathryn A. Bayles; Cheryl K. Tomoeda; Erwin B. Mont 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract Neuropsychological changes in individuals with Parkinson's disease (PD) were studied longitudinally. Sixty‐nine idiopathic PD patients, with Mini‐Mental State Examination (MMSE) scores falling within normal range, and 37 elderly control participants were given neuropsychological tests t